← ANALYST RATINGS · TIPRANKS
Biohaven Ltd. (BHVN): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy3 Hold1 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $19.62, the highest $30.00, the lowest $10.00. The average is +82.1% from the last price of $10.78.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $19.00 | Hold | +76.3% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $10.50−4.5% | Hold | −2.6% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $11.00+4.8% | Hold | +2.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $10.50−4.5% | Hold | −2.6% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $11.00−4.3% | Hold | +2.0% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $11.00−4.3% | Hold | +2.0% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.00 → $10.50−4.5% | Hold | −2.6% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $10.50−4.5% | Hold | −2.6% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $15.00 → $11.50−23.3% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $15.00 → $11.50−23.3% | Hold | +6.7% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.50 → $11.00−24.1% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.50 → $11.00−24.1% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.50 → $11.00−24.1% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $14.50 → $11.00−24.1% | Hold | +2.0% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% | Bank of America Securities | $11.00 | Sell | +2.0% | Reiterated | 12.10.26on TipRanks 13:00 | −2.2%next day −3.3% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $21.00 | Buy | +94.8% | Reiterated | 09.10.26on TipRanks 07:11 | +0.7%next day −2.2% · 5 days −8.8% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $21.00 | Buy | +94.8% | Reiterated | 30.09.26on TipRanks 09:06 | +0.7%next day −1.8% · 5 days −12.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.50 → $15.00+3.4% | Hold | +39.1% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.50 → $15.00+3.4% | Hold | +39.1% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.00 → $14.50+3.6% | Hold | +34.5% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.00 → $14.50+3.6% | Hold | +34.5% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $14.00 → $14.50+3.6% | Hold | +34.5% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $14.00 → $14.50+3.6% | Hold | +34.5% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $17.00 | Buy | +57.7% | Reiterated | 17.09.26on TipRanks Sep 18 07:25 | +14.4%next day −2.1% · 5 days −5.9% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Buy | — | Reiterated | 13.09.26on TipRanks Sep 14 06:15 | −0.1%next day −1.9% · 5 days +10.6% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $10.00 | Hold | −7.2% | Reiterated | 10.09.26on TipRanks 12:45 | −14.1%next day −1.5% · 5 days +8.0% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | — | Buy | — | Reiterated | 10.09.26on TipRanks 11:20 | −14.1%next day −1.5% · 5 days +8.0% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Hold | — | Assigned | 09.09.26on TipRanks Sep 10 08:31 | +2.4%next day −14.1% · 5 days −18.8% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $23.00 → $19.00−17.4% | Hold | +76.3% | Downgrade | 08.09.26on TipRanks 05:30 | −5.6%next day +2.4% · 5 days −15.0% | ↗ |
| Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% | Bank of America Securities | $11.00 | Sell | +2.0% | Reiterated | 26.08.26on TipRanks Aug 27 04:35 | +17.8%next day −5.6% · 5 days −7.3% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $30.00 | Buy | +178.3% | Reiterated | 17.08.26on TipRanks 07:38 | −0.8%next day −5.5% · 5 days −4.2% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $19.00 | Buy | +76.3% | Reiterated | 12.08.26on TipRanks 07:50 | −0.9%next day +2.5% · 5 days −1.3% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $30.00 | Buy | +178.3% | Reiterated | 11.08.26on TipRanks Aug 12 02:40 | 0.0%next day −0.9% · 5 days −5.9% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $15.00 → $20.00+33.3% | Buy | +85.5% | Assigned | 26.06.26on TipRanks 08:40 | +3.9%next day −7.2% · 5 days −1.7% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $27.00 → $25.00−7.4% | Buy | +131.9% | Reiterated | 28.05.26on TipRanks May 29 09:15 | −9.9%next day +7.3% · 5 days +11.0% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $11.00 | Hold | +2.0% | Reiterated | 28.05.26on TipRanks May 29 06:10 | −9.9%next day +7.3% · 5 days +11.0% | ↗ |
| Unknown Analyst | Bernstein | $9.00 | Hold | −16.5% | Reiterated | 13.05.26on TipRanks 08:10 | −2.4%next day −0.9% · 5 days −1.8% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $50.00 → $15.00−70.0% | Buy | +39.1% | Reiterated | 25.12.25on TipRanks Dec 26 06:25 | +3.2%next day +3.9% · 5 days −10.6% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $16.00 | Buy | +48.4% | Reiterated | 17.11.25on TipRanks Nov 18 07:50 | +0.6%next day +15.1% · 5 days +16.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Biohaven Ltd.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.62 at a price of $13.35 (+47.0%); now: $19.62 at $10.78 (+82.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 11 | 9 | 5 | 5 | 6 |
| Buy | 2 | 5 | 5 | 8 | 7 | 7 |
| Hold | 13 | 9 | 9 | 5 | 7 | 8 |
| Sell | 0 | 1 | 1 | 2 | 1 | 2 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.61 (from $-0.90 to $1.47). Last quarter: $-0.91.
Best top-analyst consensus in the sector · Healthcare
About Biohaven Ltd.
- CEO: Vladimir Coric
- Employees: 274
- 215 Church Street, New Haven, CT, 06510, US
- www.biohaven.com
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗